CamBP in the UK collaborates with BTG on obesity treatment
BTG is to assign IP for technology related to the production of antiadipocyte antibodies for the treatment of obesity to privately owned UK biotechnology company CamBP (formerly the Cambridge Bioscience Partnership). The move follows on from a previous study on antiadipocyte antibodies seed funded by BTG.
BTG is to assign IP for technology related to the production of antiadipocyte antibodies for the treatment of obesity to privately owned UK biotechnology company CamBP (formerly the Cambridge Bioscience Partnership). The move follows on from a previous study on antiadipocyte antibodies seed funded by BTG.
CamBP focuses on accelerating drug development for central nervous system diseases and metabolic disorders. It in-licenses compounds and technology at the discovery stage with the intention of out-licensing its preclinical or Phase I drug development candidates to pharmaceutical or biotechnology customers.
BTG, which operates from London, the US and Japan, acquires rights to early stage pharmaceuticals and other medical technologies and funds and manages outsourced preclinical and clinical development programmes. It has some 50 projects at varying stages of development in its pipeline.